SEOUL, South Korea, June 3, 2026 /PRNewswire/ -- MEDIPOST, a fully integrated commercial stage cell therapy biotechnology company, announced today that it has secured the FDA's agreement to conduct a single pivotal Phase 3 study for CARTISTEM® in the U.S. This milestone marks a...
Hence then, the article about medipost secures fda agreement on single pivotal phase 3 study with confirmatory evidence bla filing strategy for cartistem in the u s was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( MEDIPOST Secures FDA Agreement on Single Pivotal Phase 3 Study with Confirmatory Evidence BLA Filing Strategy for CARTISTEM® in the U.S. )
Also on site :
- Man who died in Stanislaus County trench incident near Hickman identified by family
- Statement from Bradley Tusk In Response to 15-Year-Old Girl Killed While Riding Electric Citi Bike in East Village
- Melissa Barrera Says Support for Macklemore After He Was Dropped from Ed Sheeran’s Tour Is ‘Beautiful’ and ‘I Didn’t Get That’ After Being Fired From ‘Scream’